Vaxcyte reports positive OPUS-1 topline data for VAX-31, outlines BLA path to first half of 2028Nov 4Quarterly updateVaxcyte, Inc.
Vaxcyte prices $500M convertible notes and stock offering after VAX-31 Phase 3 winOct 8Clinical readoutVaxcyte, Inc.Updated
Vaxcyte names new chief medical and legal officers, moves up OPUS-1 data timingSep 3Clinical readoutVaxcyte, Inc.
Vaxcyte reports Q2 2026 results, OPUS Phase 3 trials fully enrolled, initiates VAX-A1 Phase 1Aug 5Quarterly updateVaxcyte, Inc.